Cagrilintide 5mg + Semaglutide 5mg (Blend)

{"type"=>"root", "children"=>[{"type"=>"paragraph", "children"=>[{"type"=>"text", "value"=>"Retatrutide may still be more effective as a single compound. CagriSema offers a different mechanistic approach."}]}]}

{"type"=>"root", "children"=>[{"type"=>"paragraph", "children"=>[{"type"=>"text", "value"=>"CagriSema™ (investigational name)"}]}, {"type"=>"paragraph", "children"=>[{"type"=>"text", "value"=>"No brand name yet"}]}, {"type"=>"paragraph", "children"=>[{"type"=>"text", "value"=>"Manufacturer: Novo Nordisk"}]}, {"type"=>"paragraph", "children"=>[{"type"=>"text", "value"=>"REDEFINE Phase 3 ongoing"}]}]}

{"type"=>"root", "children"=>[{"type"=>"paragraph", "children"=>[{"type"=>"text", "value"=>"Combined side effect profile of both: nausea (up to 45%), GI effects more pronounced than either alone"}]}]}

{"type"=>"root", "children"=>[{"type"=>"list", "listType"=>"unordered", "children"=>[{"type"=>"list-item", "children"=>[{"type"=>"text", "value"=>"Do NOT combine with any other GLP-1 agonist (Tirzepatide, Retatrutide, standalone Semaglutide)"}]}, {"type"=>"list-item", "children"=>[{"type"=>"text", "value"=>"Already a dual-mechanism compound — adding more = toxicity not efficacy"}]}]}]}

{"type"=>"root", "children"=>[{"type"=>"list", "listType"=>"unordered", "children"=>[{"type"=>"list-item", "children"=>[{"type"=>"text", "value"=>"Frias et al. (2023) CagriSema Phase 2 in T2D. NEJM 389:1151-62. DOI: 10.1056/NEJMoa2306584"}]}, {"type"=>"list-item", "children"=>[{"type"=>"text", "value"=>"REDEFINE Phase 3 program ongoing (Novo Nordisk)"}]}, {"type"=>"list-item", "children"=>[{"type"=>"text", "value"=>"NOT YET FDA APPROVED"}]}, {"type"=>"list-item", "children"=>[{"type"=>"text", "value"=>"ClinicalTrials.gov: NCT05567796"}]}]}]}

{"type"=>"root", "children"=>[{"type"=>"paragraph", "children"=>[{"type"=>"text", "value"=>"CagriSema combination. Dual-mechanism weight loss targeting both GLP-1 and amylin pathways simultaneously. Clinical trials showed ~25% weight loss. Potentially the most effective approved-pathway combination."}]}]}

{"type"=>"root", "children"=>[{"type"=>"paragraph", "children"=>[{"type"=>"text", "value"=>"Dual pathway: amylin + GLP-1. Targets two separate satiety mechanisms for additive weight loss effect."}]}]}

{"type"=>"root", "children"=>[{"type"=>"list", "listType"=>"unordered", "children"=>[{"type"=>"list-item", "children"=>[{"type"=>"text", "value"=>"5mg+5mg (only size)"}]}]}, {"type"=>"paragraph", "children"=>[{"type"=>"text", "value"=>"Duration depends on dose titration. Monitor shelf life carefully during low-dose phases."}]}]}

{"type"=>"root", "children"=>[{"type"=>"paragraph", "children"=>[{"type"=>"text", "value"=>"EARLY: ", "bold"=>true}, {"type"=>"text", "value"=>"1-2 weeks"}]}, {"type"=>"paragraph", "children"=>[{"type"=>"text", "value"=>"FULL: ", "bold"=>true}, {"type"=>"text", "value"=>"16-32 weeks"}]}, {"type"=>"paragraph", "children"=>[{"type"=>"text", "value"=>"Dual mechanism means effects may be felt slightly faster than either compound alone."}]}, {"type"=>"paragraph", "children"=>[{"type"=>"text", "value"=>"Week 1-2: Appetite suppression from both pathways."}]}, {"type"=>"paragraph", "children"=>[{"type"=>"text", "value"=>"Week 4-8: Visible weight loss."}]}, {"type"=>"paragraph", "children"=>[{"type"=>"text", "value"=>"Week 16-32: ~25% body weight loss in trials at 32 weeks."}]}, {"type"=>"paragraph", "children"=>[{"type"=>"text", "value"=>"Minimum commitment: 16 weeks for meaningful assessment."}]}]}

{"type"=>"root", "children"=>[{"type"=>"paragraph", "children"=>[{"type"=>"text", "value"=>"Must titrate both components. Follow individual titration schedules. Consult specific CagriSema protocols."}]}]}